On August 26, 2021, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharma) announced that Dr. Xiaoli Qin was appointed as Chief Scientific Officer (CSO) and promoted to Senior Vice President to lead the research and early development.

Dr. Jinfu Yang, the co-founder and President of Zenshine, said, "As an outstanding research scientist of biology and translational science, Dr. Qin gained decades of experiences in the bio-pharma industry. Dr. Qin will lead the research and development team to speed up our research pipeline and launch more milestone events. We expect that Dr. Qin will burst into bloom in her new role and reshape Zenshine to be a science driven, leading innovative biotech firm with high influences globally."

"Zenshine has strong capacity for research and development. It’s my honor to be appointed as CSO of Zenshine. Definitely my team and I will work hard to speed up the research progress of current projects and enrich our new pipelines in near future. We committed to the mission of “apply the best science to serve patients”, providing bench to bed solutions and best-in-class or first-in-class therapeutic agents to patients.” said by Dr. Qin. 

Dr. Qin received her undergraduate education in Peking University and got the PhD degree from Stanford University. After years of post-doctoral research training in the University of California, Berkeley and Howard Hughes Medical Institute, she entered the bio-pharma industry in drug discovery and development, where she became an expert in the area of translational science and early clinical development in the past 20 years. Before joining Zenshine, Dr. Qin served as Senior Director in Curegenix and Senior Scientist in InterMune. During that time, Dr. Qin successfully led or participated in development of 5 NCEs to the clinical stage. 
 

About Zenshine Pharma

Zenshine Pharma is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.